Pascale Dutailly
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
Journal: European urology
Published: March 14, 2025
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).
Journal: Clinical genitourinary cancer
Published: September 02, 2024
Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Journal: Clinical genitourinary cancer
Published: October 05, 2023
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Journal: Future oncology (London, England)
Published: July 05, 2023
Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
Journal: Advances in therapy
Published: October 17, 2016
Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation .
Journal: Hormone research in paediatrics
Published: September 28, 2016
Not Available
Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Published: October 14, 2015
Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.
Journal: Therapeutic advances in urology
Published: July 11, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026